CDKN2A and neoplasm: Importantly, four of the eight tumours with CDKN2A/B homozygous deletion were well-defined, four demonstrated ≥25% T2-FLAIR mismatch, only one demonstrated solid enhancement (with two further tumours demonstrating wispy enhancement), and none had MRI evidence of necrosis.